KMTS (Kestra Medical Technologies) Other Financing: $148.13 Mil (TTM As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KMTS Kestra Medical Technologies Ltd KMTS
10 GF Score
Price $24.24
! 4 Warning Signs
View Full Analysis

What is Kestra Medical Technologies Other Financing?

Kestra Medical Technologies KMTS -2.34% 10 Other Financing is $148.13 Mil as of Jan. 2026. GuruFocus rates KMTS with a GF Score™ of 10/100. The stock has 4 warning signs investors should review.

Kestra Medical Technologies's Other Financing for the three months ended in Jan. 2026 was $149.21 Mil.

Kestra Medical Technologies's Other Financing for the trailing twelve months (TTM) ended in Jan. 2026 was $148.13 Mil.

Kestra Medical Technologies Other Financing Historical Data

* Premium members only.

The historical data trend for Kestra Medical Technologies's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kestra Medical Technologies Other Financing Chart

Kestra Medical Technologies Annual Data
Trend Apr20 Apr21 Apr23 Apr24
Other Financing
30.42 29.00 0.00 -2.35

Kestra Medical Technologies Quarterly Data
Apr20 Jul20 Apr21 Jul21 Apr23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -1.08 0.00 0.00 149.21
KMTS
10GF Score
Kestra Medical Technologies Ltd KMTS
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kestra Medical Technologies Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $148.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $148.13 Mil mean?
Kestra Medical Technologies (KMTS) has a Other Financing of $148.13 Mil as of Jan. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Kestra Medical Technologies and its competitors.
Is Kestra Medical Technologies' Other Financing too high?
Kestra Medical Technologies' current Other Financing is $148.13 Mil. Overall, Kestra Medical Technologies has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Kestra Medical Technologies' Other Financing compare to ATRC and STAA?
Kestra Medical Technologies' Other Financing of $148.13 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Medical Devices & Instruments company?
A good Other Financing depends on the Medical Devices & Instruments industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Kestra Medical Technologies and its competitors. Kestra Medical Technologies's current Other Financing is $148.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kestra Medical Technologies stock overvalued right now?
Kestra Medical Technologies (KMTS) has a current Other Financing of $148.13 Mil. The current Other Financing is $148.13 Mil. Kestra Medical Technologies' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Kestra Medical Technologies (KMTS), the current Other Financing is $148.13 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kestra Medical Technologies Business Description

Address 3933 Lake Washington Boulevard NE, Suite 200, Kirkland, WA, USA, 98033
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
10GF Score

Get the complete analysis for KMTS

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.24
Price